ClinicalTrials.gg
CompletedNCT01730040Updated Aug 31, 2015Results posted

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

A Phase 3 interventional study of Alirocumab and Atorvastatin in Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Completed at 97 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-31.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
355
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
12th of 43
355 · median 107
Started
2012
with 11 others
Phase 3
20 of 43
none open now
Registered
19th of 43
by date
Lead sponsor
11 of 43
Regeneron Pharmaceuticals

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 12th largest by enrollment, is one of 12 that started in 2012, is one of 20 in phase 3, and was the 19th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

This is a randomized, double-blind, active-comparator, parallel-group study in patients at high cardiovascular risk with nonfamilial hypercholesterolemia or heterozygous familial hypercholesterolemia (heFH).

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with screening (visit 1) LDL-C greater than or equal to 70 mg/dL with documented CVD, not adequately controlled with a daily dose of atorvastatin. OR
  2. Patients with screening (visit 1) LDL-C greater than or equal to 100 mg/dL at high risk for CVD who are not adequately controlled with a daily dose of atorvastatin.

Exclusion criteria

Exclusion Criteria:

  1. LDL-C greater than 250 mg/dL
  2. LDL-C less than 70 mg/dL at the screening visit in patients with history of documented CVD
  3. LDL-C less than 100 mg/dL at the screening visit in patients without history of documented CHD or non-CHD CVD, but with other risk factors
  4. TG greater than 400 mg/dL
  5. Homozygous FH (clinically or previous genotyping)
  6. Currently taking a statin that is not atorvastatin
  7. Currently taking Ezetimibe (EZE)
  8. Not on a stable dose of allowable lipid modifying treatments (LMT)

(The inclusion/ exclusion criteria provided above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
355 participants (actual)

Study arms

  • Active comparator
    Atorvastatin 40 mg

    Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received atorvastatin 40 mg over-encapsulated tablets orally once daily (QD), placebo for alirocumab SC injection every two weeks (Q2W), and placebo for ezetimibe over-encapsulated tablets orally QD added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.

    Drug: Atorvastatin · Drug: Placebo

  • Active comparator
    Ezetimibe 10 mg + Atorvastatin 20 mg

    Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received ezetimibe 10 mg over-encapsulated tablets orally QD, atorvastatin 20 mg over-encapsulated tablets orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.

    Drug: Atorvastatin · Drug: Ezetimibe · Drug: Placebo

  • Experimental
    Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg

    Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received Alirocumab 75 mg SC injection Q2W, atorvastatin 20 mg over-encapsulated tablets orally QD, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.

    Drug: Alirocumab · Drug: Atorvastatin · Drug: Placebo

  • Active comparator
    Atorvastatin 80 mg

    Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received Atorvastatin 80 mg over-encapsulated tablets orally QD, placebo for alirocumab SC injection Q2W, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks.

    Drug: Atorvastatin · Drug: Placebo

  • Active comparator
    Rosuvastatin 40 mg

    Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received rosuvastatin 40 mg over-encapsulated tablets orally QD, placebo for alirocumab SC injection Q2W, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks.

    Drug: Rosuvastatin · Drug: Placebo

  • Active comparator
    Ezetimibe 10 mg + Atorvastatin 40 mg

    Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received ezetimibe 10 mg over-encapsulated tablets orally QD, atorvastatin 40 mg over-encapsulated tablets orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.

    Drug: Atorvastatin · Drug: Ezetimibe · Drug: Placebo

  • Experimental
    Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg

    Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received alirocumab 75 mg SC injection Q2W, atorvastatin 40 mg over-encapsulated tablets orally QD, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.

    Drug: Alirocumab · Drug: Atorvastatin · Drug: Placebo

Interventions

  • Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.

    Also known as: REGN727/SAR236553

  • Atorvastatin over-encapsulated tablets orally.

  • Ezetimibe over-encapsulated tablet orally.

    Also known as: Ezetrol

  • Rosuvastatin over-encapsulated tablets orally.

    Also known as: Crestor

  • DrugPlacebo

    Placebo for alirocumab and ezetimibe.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis

    Calculated LDL-C values were obtained from Friedewald formula. Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 24

Secondary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis

    Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first) (on-treatment analysis).

    Time frame: From Baseline to Week 24

  2. Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis

    Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment (ITT analysis).

    Time frame: From Baseline to Week 24

  3. Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis

    Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first) (on-treatment analysis).

    Time frame: From Baseline to Week 24

  4. Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  5. Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (ie. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first).

    Time frame: From Baseline to Week 24

  6. Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  7. Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first).

    Time frame: From Baseline to Week 24

  8. Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  9. Percent Change From Baseline in Apo B at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  10. Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  11. Percent Change From Baseline in Total-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  12. Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis

    Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).

    Time frame: Up to Week 24

  13. Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis

    Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first (on-treatment analysis).

    Time frame: Up to Week 24

  14. Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis

    Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).

    Time frame: Up to Week 24

  15. Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis

    Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first (on-treatment analysis).

    Time frame: Up to Week 24

  16. Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 from from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  17. Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  18. Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 from from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  19. Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  20. Percent Change From Baseline in Lipoprotein(a) at Week 12 - ITT Analysis

    Adjusted means and standard errors at Week 12 from from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  21. Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  22. Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis

    Adjusted means and standard errors at Week 12 from from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  23. Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

07

Results

Posted Aug 31, 2015

Participant flow

The study was conducted at 85 sites in 9 countries. Overall, 859 subjects were screened between 24 October 2012 and 26 September 2013, 504 of whom were screen failures. Screen failures ware mainly due to exclusion criteria met.

Participant flow — Overall Study
MilestoneAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Started57555747454747
Treated57555747454647
Completed44404639394038
Not completed1315118679
Withdrew: Randomized but not treated0000010
Withdrew: Subject moved0010001
Withdrew: Physician decision0000011
Withdrew: Other than specified7855544
Withdrew: Adverse event4353112
Withdrew: Poor compliance to protocol2400001

Outcome measures

PrimaryPercent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis

Calculated LDL-C values were obtained from Friedewald formula. Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis
percent changeAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis-5 ± 4.6-20.5 ± 4.7-44.1 ± 4.5-4.8 ± 4.2-21.4 ± 4.2-22.6 ± 4.3-54 ± 4.3
Statistical analysis
  • Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = < 0.0001 · Ls mean difference: -39.1 · 99% CI -55.9 to -22.2Threshold for significance ≤ 0.01.
  • Ezetimibe 10 mg + Atorvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = = 0.0004 (Threshold for significance ≤ 0.01.) · Ls mean difference: -23.6 · 99% CI -40.7 to -6.5
  • Atorvastatin 80 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = < 0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -49.2 · 99% CI -65 to -33.5
  • Rosuvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = < 0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -32.6 · 99% CI -48.4 to -16.9
  • Ezetimibe 10 mg + Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -31.4 · 99% CI -47.4 to -15.4
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis

Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first) (on-treatment analysis).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis
percent changeAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis-6.1 ± 4.6-23.7 ± 4.7-48.6 ± 4.5-5.0 ± 4.4-22.9 ± 4.4-24.5 ± 4.5-57.8 ± 4.5
Statistical analysis
  • Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = < 0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -42.5 · 99% CI -59.2 to -25.7
  • Ezetimibe 10 mg + Atorvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = = 0.0002 (Threshold for significance≤ 0.01.) · Ls mean difference: -24.9 · 99% CI -41.9 to -7.8
  • Atorvastatin 80 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = < 0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -52.8 · 99% CI -69.2 to -36.5
  • Rosuvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = < 0.0001 · Ls mean difference: -35.0 · 99% CI -51.3 to -18.6Threshold for significance ≤ 0.01.
  • Ezetimibe 10 mg + Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = < 0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -33.4 · 99% CI -50.0 to -16.8
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis

Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment (ITT analysis).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
percent changeAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis-8.5 ± 3.9-22.6 ± 3.9-48.4 ± 3.8-14.5 ± 3.2-23.3 ± 3.2-29.7 ± 3.2-50.5 ± 3.2
Statistical analysis
  • Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -39.8 · 99% CI -54 to -25.6
  • Ezetimibe 10 mg + Atorvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -25.8 · 99% CI -40.0 to -11.6
  • Atorvastatin 80 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -36.0 · 99% CI -47.7 to -24.3
  • Rosuvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -27.3 · 99% CI -39.2 to -15.4
  • Ezetimibe 10 mg + Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -20.9 · 99% CI -32.8 to -8.9
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis

Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first) (on-treatment analysis).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis
percent changeAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis-9.2 ± 3.1-27.1 ± 3.1-53.7 ± 3.1-14.6 ± 3.2-23.3 ± 3.2-30.7 ± 3.2-50.9 ± 3.2
Statistical analysis
  • Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -44.5 · 99% CI -55.8 to -33.1
  • Ezetimibe 10 mg + Atorvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -26.6 · 99% CI -38.0 to -15.2
  • Atorvastatin 80 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -36.3 · 99% CI -48.1 to -24.5
  • Rosuvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -27.7 · 99% CI -39.6 to -15.8
  • Ezetimibe 10 mg + Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -20.2 · 99% CI -32.2 to -8.2
SecondaryPercent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis
percent changeAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis-4.4 ± 3.5-10.1 ± 3.6-33.7 ± 3.4-3.5 ± 3.3-10.9 ± 3.2-14.3 ± 3.3-41.9 ± 3.4
Statistical analysis
  • Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -29.3 · 99% CI -42.0 to -16.6
  • Ezetimibe 10 mg + Atorvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -23.6 · 99% CI -36.6 to -10.7
  • Atorvastatin 80 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -38.4 · 99% CI -50.8 to -26.0
  • Rosuvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -30.9 · 99% CI -43.2 to -18.6
  • Ezetimibe 10 mg + Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -27.6 · 99% CI -40.1 to -15.1
SecondaryPercent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (ie. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis
percent changeAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis-5.1 ± 3.3-12.6 ± 3.5-37.7 ± 3.2-4.4 ± 3.4-12.8 ± 3.4-16.3 ± 3.4-42.7 ± 3.5
Statistical analysis
  • Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -32.6 · 99% CI -44.6 to -20.6
  • Ezetimibe 10 mg + Atorvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -25.1 · 99% CI -37.3 to -12.8
  • Atorvastatin 80 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -38.3 · 99% CI -51.2 to -25.4
  • Rosuvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -29.8 · 99% CI -42.6 to -17.1
  • Ezetimibe 10 mg + Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -26.4 · 99% CI -39.4 to -13.4
SecondaryPercent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
percent changeAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis-6.3 ± 3.9-15.1 ± 4.0-36.7 ± 3.9-6.5 ± 3.6-17.4 ± 3.6-21.0 ± 3.7-47.6 ± 3.7
Statistical analysis
  • Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -30.4 · 99% CI -44.7 to -16.1
  • Ezetimibe 10 mg + Atorvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = =0.0002 (Threshold for significance ≤ 0.01.) · Ls mean difference: -21.6 · 99% CI -36.1 to -7.1
  • Atorvastatin 80 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -41.1 · 99% CI -54.7 to -27.5
  • Rosuvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -30.2 · 99% CI -43.7 to -16.6
  • Ezetimibe 10 mg + Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -26.6 · 99% CI -40.3 to -12.8
SecondaryPercent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis
percent changeAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis-7.5 ± 3.8-18.1 ± 4.0-40.5 ± 3.7-7.0 ± 3.7-18.4 ± 3.7-23.3 ± 3.8-50.5 ± 3.8
Statistical analysis
  • Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -33.0 · 99% CI -47.0 to -19.0
  • Ezetimibe 10 mg + Atorvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -22.4 · 99% CI -36.6 to -8.1
  • Atorvastatin 80 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -43.6 · 99% CI -57.4 to -29.7
  • Rosuvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -32.1 · 99% CI -46.0 to -18.3
  • Ezetimibe 10 mg + Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -27.3 · 99% CI -41.4 to -13.2
SecondaryPercent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
percent changeAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis-4.0 ± 2.7-11.2 ± 2.8-27.1 ± 2.7-4.8 ± 2.8-11.7 ± 2.8-15.2 ± 2.9-33.6 ± 2.9
Statistical analysis
  • Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -23.1 · 99% CI -32.9 to -13.2
  • Ezetimibe 10 mg + Atorvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -15.8 · 99% CI -25.8 to -5.8
  • Atorvastatin 80 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -28.9 · 99% CI -39.4 to -18.4
  • Rosuvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -21.9 · 99% CI -32.4 to -11.4
  • Ezetimibe 10 mg + Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -18.4 · 99% CI -29.1 to -7.7
SecondaryPercent Change From Baseline in Apo B at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
percent changeAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis-6.9 ± 2.8-13.1 ± 2.8-38.4 ± 2.7-9.5 ± 2.5-14.1 ± 2.5-20.3 ± 2.5-36.2 ± 2.5
Statistical analysis
  • Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -31.5 · 99% CI -41.6 to -21.3
  • Ezetimibe 10 mg + Atorvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -25.3 · 99% CI -35.4 to -15.2
  • Atorvastatin 80 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -26.7 · 99% CI -35.9 to -17.5
  • Rosuvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -22.2 · 99% CI -31.5 to -12.9
  • Ezetimibe 10 mg + Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -15.9 · 99% CI -25.2 to -6.6
SecondaryPercent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
percent changeAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis-7.1 ± 3.2-17.2 ± 3.2-40.6 ± 3.2-13.0 ± 2.6-19.8 ± 2.7-27.5 ± 2.7-42.3 ± 2.7
Statistical analysis
  • Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -33.5 · 99% CI -45.3 to -21.6
  • Ezetimibe 10 mg + Atorvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -23.4 · 99% CI -35.2 to -11.6
  • Atorvastatin 80 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -29.3 · 99% CI -39.0 to -19.6
  • Rosuvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -22.5 · 99% CI -32.3 to -12.7
  • Ezetimibe 10 mg + Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -14.8 · 99% CI -24.7 to -4.9
SecondaryPercent Change From Baseline in Total-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
percent changeAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis-6.5 ± 2.4-13.2 ± 2.4-29.0 ± 2.4-9.9 ± 2.1-13.5 ± 2.1-19.2 ± 2.1-29.0 ± 2.1
Statistical analysis
  • Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -22.6 · 99% CI -31.4 to -13.8
  • Ezetimibe 10 mg + Atorvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -15.8 · 99% CI -24.6 to -7.0
  • Atorvastatin 80 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -19.1 · 99% CI -26.9 to -11.4
  • Rosuvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.01.) · Ls mean difference: -15.4 · 99% CI -23.3 to -7.6
  • Ezetimibe 10 mg + Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = =0.0015 (Threshold for significance ≤ 0.01.) · Ls mean difference: -9.8 · 99% CI -17.7 to -1.9
SecondaryPercentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis

Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis
percentage of participantsAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis34.568.487.218.562.265.184.6
Statistical analysis
  • Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.01.) · Odds ratio (or): 16.7 · 99% CI 3.9 to 71.7
  • Ezetimibe 10 mg + Atorvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg · Regression, Logistic · p = =0.0284 (Threshold for significance ≤ 0.01.) · Odds ratio (or): 3.4 · 99% CI 0.8 to 14.6
  • Atorvastatin 80 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.01.) · Odds ratio (or): 83.2 · 99% CI 11.6 to 596.8
  • Rosuvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Regression, Logistic · p = =0.0025 (Threshold for significance ≤ 0.01.) · Odds ratio (or): 7.2 · 99% CI 1.3 to 38.3
  • Ezetimibe 10 mg + Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Regression, Logistic · p = =0.0011 (Threshold for significance ≤ 0.01.) · Odds ratio (or): 9.1 · 99% CI 1.6 to 52.2
SecondaryPercentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis

Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first (on-treatment analysis).

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis
percentage of participantsAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis37.872.291.218.564.066.290.0
Statistical analysis
  • Atorvastatin 80 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.01.) · Odds ratio (or): 128.4 · 99% CI 14.2 to 1157
  • Rosuvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Regression, Logistic · p = =0.0015 (Threshold for significance ≤ 0.01.) · Odds ratio (or): 10.9 · 99% CI 1.6 to 75.4
  • Ezetimibe 10 mg + Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Regression, Logistic · p = =0.0008 (Threshold for significance ≤ 0.01.) · Odds ratio (or): 13.7 · 99% CI 1.8 to 101.1
SecondaryPercentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis

Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
percentage of participantsAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis16.050.379.210.242.254.277.2
Statistical analysis
  • Atorvastatin 80 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.01.) · Odds ratio (or): 116.8 · 99% CI 14.7 to 927.5
  • Rosuvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.01.) · Odds ratio (or): 13.2 · 99% CI 2.5 to 68.8
  • Ezetimibe 10 mg + Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Regression, Logistic · p = =0.0004 (Threshold for significance ≤ 0.01.) · Odds ratio (or): 9.9 · 99% CI 1.9 to 51.9
SecondaryPercentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis

Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first (on-treatment analysis).

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis
percentage of participantsAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis20.055.182.310.542.455.383.7
Statistical analysis
  • Atorvastatin 80 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.01.) · Odds ratio (or): 162.1 · 99% CI 17.3 to 1520.5
  • Rosuvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.01.) · Odds ratio (or): 19.8 · 99% CI 3.1 to 126.3
  • Ezetimibe 10 mg + Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Regression, Logistic · p = =0.0002 (Threshold for significance ≤ 0.01.) · Odds ratio (or): 13.9 · 99% CI 2.2 to 88.1
SecondaryPercent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 from from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis
percent changeAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis-20.2 ± 4.0-10.6 ± 4.4-23.6 ± 4.0-9.7 ± 4.1-4.9 ± 3.70.2 ± 3.9-30.8 ± 4.1
Statistical analysis
  • Atorvastatin 80 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Regression, Robust · p = =0.0004 (Threshold for significance ≤ 0.01.) · Adjusted mean difference: -21.1 · 99% CI -36.3 to -5.9
  • Rosuvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Regression, Robust · p = <0.0001 (Threshold for significance ≤ 0.01.) · Adjusted mean difference: -25.9 · 99% CI -40.2 to -11.6
  • Ezetimibe 10 mg + Atorvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Regression, Robust · p = <0.0001 (Threshold for significance ≤ 0.01.) · Adjusted mean difference: -31.0 · 99% CI -45.6 to -16.4
SecondaryPercent Change From Baseline in HDL-C at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
percent changeAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis1.9 ± 2.0-0.1 ± 2.14.8 ± 2.04.7 ± 2.75.7 ± 2.72.0 ± 2.77.7 ± 2.7
Statistical analysis
  • Atorvastatin 80 mg vs Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg · Mixed Models Analysis · p = =0.4456 (Threshold for significance ≤ 0.01.) · Ls mean difference: 2.9 · 99% CI -7.0 to 12.9
SecondaryPercent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 from from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
percent changeAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis-6.7 ± 3.7-3.3 ± 4.1-12.0 ± 3.7-7.3 ± 4.1-0.5 ± 4.0-13.9 ± 4.1-19.1 ± 4.10
SecondaryPercent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis
percent changeAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis1.2 ± 1.51.0 ± 1.67.6 ± 1.52.2 ± 2.04.7 ± 1.9-1.8 ± 1.95.8 ± 2.0
SecondaryPercent Change From Baseline in Lipoprotein(a) at Week 12 - ITT Analysis

Adjusted means and standard errors at Week 12 from from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein(a) at Week 12 - ITT Analysis
percent changeAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percent Change From Baseline in Lipoprotein(a) at Week 12 - ITT Analysis-11.7 ± 4.0-5.4 ± 4.0-24.0 ± 4.0-1.6 ± 4.511.5 ± 4.67.9 ± 4.5-27.9 ± 4.5
SecondaryPercent Change From Baseline in HDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
percent changeAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis-3.2 ± 1.8-1.7 ± 1.84.1 ± 1.83.0 ± 2.64.6 ± 2.74.6 ± 2.78.5 ± 2.7
SecondaryPercent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis

Adjusted means and standard errors at Week 12 from from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
percent changeAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis-4.7 ± 4.20.5 ± 4.2-12.4 ± 4.2-4.6 ± 4.0-3.7 ± 4.1-16.8 ± 4.0-12.1 ± 4.0
SecondaryPercent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis
percent changeAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis-0.8 ± 1.51.7 ± 1.45.4 ± 1.41.6 ± 1.75.6 ± 1.71.6 ± 1.79.4 ± 1.7

Adverse events

Collected over From Baseline up to Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atorvastatin 40 mg—2/57 (3.5%)17/57 (29.8%)
Ezetimibe 10 mg + Atorvastatin 20 mg—5/55 (9.1%)24/55 (43.6%)
Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg—3/57 (5.3%)15/57 (26.3%)
Atorvastatin 80 mg—4/47 (8.5%)18/47 (38.3%)
Rosuvastatin 40 mg—2/45 (4.4%)23/45 (51.1%)
Ezetimibe 10 mg + Atorvastatin 40 mg—2/46 (4.3%)12/46 (26.1%)
Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg—1/47 (2.1%)19/47 (40.4%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Angina unstableCardiac disorders0/570/552/570/470/450/460/47
Non-Cardiac chest painGeneral disorders0/570/550/570/471/450/460/47
Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/570/550/570/471/450/460/47
Coronary artery diseaseCardiac disorders0/570/550/570/470/451/460/47
PneumoniaInfections and infestations0/571/550/571/470/451/460/47
Atrioventricular block completeCardiac disorders0/570/550/571/470/450/460/47
HyperglycaemiaMetabolism and nutrition disorders0/570/550/571/470/450/460/47
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/570/550/571/470/450/460/47
Aortic aneurysmVascular disorders0/570/550/570/470/450/461/47
Cardiac arrestCardiac disorders0/571/550/570/470/450/460/47
Most frequent other events
Showing 10 of 16
Most frequent other events
EventAtorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg
Upper respiratory tract infectionInfections and infestations2/574/552/572/473/455/463/47
HypertensionVascular disorders0/571/552/571/470/455/463/47
NauseaGastrointestinal disorders3/573/551/575/473/451/460/47
Urinary tract infectionInfections and infestations3/575/551/574/471/453/462/47
NasopharyngitisInfections and infestations1/573/551/573/474/450/464/47
Back painMusculoskeletal and connective tissue disorders2/573/553/572/472/450/464/47
DiarrhoeaGastrointestinal disorders4/571/551/571/473/452/461/47
Muscle spasmsMusculoskeletal and connective tissue disorders0/571/554/571/471/450/460/47
InfluenzaInfections and infestations1/571/551/570/473/450/462/47
Accidental overdoseInjury, poisoning and procedural complications2/572/550/572/473/450/463/47

Baseline characteristics

Age, Continuous
Age, Continuous(years)Atorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mgTotal
Mean63 ± 9.9165.7 ± 8.9662.2 ± 10.0363.2 ± 10.8957.5 ± 9.9663.9 ± 10.3364.2 ± 10.3662.9 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Atorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mgTotal
Female22242414131116124
Male35313333323631231
Low density lipoprotein cholesterol (LDL-C) in mg/dL
Low density lipoprotein cholesterol (LDL-C) in mg/dL(mg/dL)Atorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mgTotal
Mean100.3 ± 29.8100.4 ± 29.5103.9 ± 34.9108.6 ± 37.5109.8 ± 39.098.9 ± 29.2116.4 ± 37.4105.1 ± 34.1
LDL-C in mmol/L
LDL-C in mmol/L(mmol/L)Atorvastatin 40 mgEzetimibe 10 mg + Atorvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Atorvastatin 20 mgAtorvastatin 80 mgRosuvastatin 40 mgEzetimibe 10 mg + Atorvastatin 40 mgAlirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mgTotal
Mean2.957 ± 0.7732.599 ± 0.7652.692 ± 0.9052.813 ± 0.972.844 ± 1.0112.562 ± 0.7563.016 ± 0.9682.723 ± 0.884
08

Study locations

97 sites
  • Mobile, Alabama, United States
  • Chandler, Arizona, United States
  • Tucson, Arizona, United States
  • Anaheim, California, United States
  • Beverly Hills, California, United States
  • Lakeland, California, United States
  • Newport Beach, California, United States
  • Northridge, California, United States
  • Sacramento, California, United States
  • Walnut Creek, California, United States
  • Milford, Connecticut, United States
  • Atlantis, Florida, United States
  • Boca Raton, Florida, United States
  • Clearwater, Florida, United States
  • Jacksonville, Florida, United States
  • Miami (2 locations), Florida, United States
  • Oviedo, Florida, United States
  • Pinellas Park, Florida, United States
  • Port Orange, Florida, United States
  • Sarasota, Florida, United States
  • Tampa, Florida, United States
  • West Palm Beach, Florida, United States
  • Boise, Idaho, United States
  • Meridian, Idaho, United States
  • Chicago, Illinois, United States
  • Morton, Illinois, United States
  • Indianapolis, Indiana, United States
  • Newton, Kansas, United States
  • Overland Park, Kansas, United States
  • Wichita, Kansas, United States
  • Lexington, Kentucky, United States
  • Louisville, Kentucky, United States
  • Auburn, Maine, United States
  • Bethesda, Maryland, United States
  • Edina, Minnesota, United States
  • Rochester, Minnesota, United States
  • Olive Branch, Mississippi, United States
  • Port Gibson, Mississippi, United States
  • St. Louis, Missouri, United States
  • Butte, Montana, United States
  • Las Vegas, Nevada, United States
  • Williamsville, New York, United States
  • Winston-Salem, North Carolina, United States
  • Cleveland, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Warwick, Rhode Island, United States
  • Greer, South Carolina, United States
  • Summerville, South Carolina, United States
  • Kingsport, Tennessee, United States
  • Dallas (2 locations), Texas, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • Bountiful, Utah, United States
  • Marion, Utah, United States
  • Salt Lake City, Utah, United States
  • Renton, Washington, United States
  • Herston QLD, Australia
  • New Lambton Heights, Australia
  • Perth, Australia
  • Sherwood, Australia
  • Woolloongabba, Australia
  • Brampton, Ontario, Canada
  • Etobicoke, Ontario, Canada
  • London, Ontario, Canada
  • Newmarke, Ontario, Canada
  • Thornhill, Ontario, Canada
  • Toronto, Ontario, Canada
  • Chicoutimi, Quebec, Canada
  • Dijon, France
  • Lille, France
  • Venissieux, France
  • Bad Oeynhausen, Germany
  • Berlin, Germany
  • Koeln, Germany
  • Munich, Germany
  • Regensburg, Germany
  • Ulm, Germany
  • Chiete, Italy
  • Genova, Italy
  • Napoli, Italy
  • Palermo, Italy
  • Roma (2 locations), Italy
  • Distrito Federal, Mexico
  • Guadalajara, Jalisco, Mexico
  • Guadalajara, Mexico
  • Monterrey Nuevo Leon, Mexico
  • Tijuana Baja California, Mexico
  • Zapopan Jalisco, Mexico
  • Barcelona (3 locations), Spain
  • Madrid, Spain
  • Sant Joan Despi, Spain
  • Carmarthen, United Kingdom
  • Chester, United Kingdom
  • Peterborough, United Kingdom
  • Salford, United Kingdom
  • Stevenage, United Kingdom
  • West Bromwich, West Midlands, United Kingdom
09

References and documents

Publications

  • Mahmood T, Minnier J, Ito MK, Li QH, Koren A, Kam IW, Fazio S, Shapiro MD. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. Eur J Prev Cardiol. 2021 Jul 23;28(8):816-822. doi: 10.1177/2047487320915803. Epub 2020 Apr 10. PubMed 34298554 ↗
  • Leiter LA, Tinahones FJ, Karalis DG, Bujas-Bobanovic M, Letierce A, Mandel J, Samuel R, Jones PH. Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Diabet Med. 2018 Dec;35(12):1742-1751. doi: 10.1111/dme.13817. Epub 2018 Oct 9. PubMed 30183102 ↗
  • Ray KK, Ginsberg HN, Davidson MH, Pordy R, Bessac L, Minini P, Eckel RH, Cannon CP. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016 Dec 13;134(24):1931-1943. doi: 10.1161/CIRCULATIONAHA.116.024604. Epub 2016 Oct 24. PubMed 27777279 ↗
  • Bays H, Gaudet D, Weiss R, Ruiz JL, Watts GF, Gouni-Berthold I, Robinson J, Zhao J, Hanotin C, Donahue S. Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. J Clin Endocrinol Metab. 2015 Aug;100(8):3140-8. doi: 10.1210/jc.2015-1520. Epub 2015 Jun 1. PubMed 26030325 ↗
  • Robinson JG, Colhoun HM, Bays HE, Jones PH, Du Y, Hanotin C, Donahue S. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies. Clin Cardiol. 2014 Oct;37(10):597-604. doi: 10.1002/clc.22327. Epub 2014 Sep 30. PubMed 25269777 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Apr 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 1 year 4 months after primary completion. A results delay was requested in Jan 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2012
First posted
Nov 21, 2012
Start
Oct 2012
Primary completionActual
Apr 2014
CompletionActual
May 2014
Results delay requested
Jan 24, 2015
Results first posted
Aug 31, 2015
Last update
Aug 31, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01730040
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Nov 21, 2012
Start date
Oct 2012
Primary completion
Apr 2014
Completion
May 2014
Results posted
Aug 31, 2015
Last update
Aug 31, 2015

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alirocumab · Atorvastatin

Start the discussion